Semaglutide vs Ozempic vs Wegovy: What's the Difference?

Semaglutide is the ingredient; Ozempic and Wegovy are products containing it. The product’s brand, formulation and indication determine its approved uses and instructions. Sharing an ingredient does not make finished products interchangeable.

This distinction matters before comparing a dose, insurance benefit or trial result. A weekly injection, a daily tablet and a compounded preparation can all mention semaglutide while requiring different decisions.

Semaglutide, Ozempic and Wegovy compared

The table summarizes U.S. indications. It is not a list of medicines offered by REMEVi.

Name and formulation	What it is	Approved-use summary
Semaglutide	Active ingredient; a GLP-1 receptor agonist	The ingredient name alone does not specify an approved product
Ozempic injection	Weekly semaglutide injection	Adult type 2 diabetes glucose control; cardiovascular-risk reduction with established cardiovascular disease; certain kidney and cardiovascular outcomes with type 2 diabetes and chronic kidney disease
Ozempic tablets	Daily oral semaglutide	Adult type 2 diabetes glucose control and major cardiovascular-risk reduction in adults with type 2 diabetes at high risk
Wegovy injection	Weekly semaglutide injection	Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular-risk reduction in eligible adults; noncirrhotic MASH with F2–F3 fibrosis in adults
Wegovy tablets	Daily oral semaglutide	Weight management and cardiovascular-risk reduction in eligible adults
Compounded semaglutide	Individually prescribed compounded preparation	Not FDA-approved; no approved indication or generic-equivalence designation

Sources: Ozempic injection, section 1, Ozempic tablets, section 1, Wegovy, section 1.

For adult weight management, Wegovy’s label covers obesity, or overweight with at least one weight-related condition. Its cardiovascular indication requires established cardiovascular disease plus obesity or overweight. MASH is a liver disease; the injection’s F2–F3 indication received accelerated approval, with continued approval contingent on confirming clinical benefit. That indication and adolescent weight treatment do not extend to Wegovy tablets.

The dose depends on the formulation

Ozempic injection has a maximum labeled dose of 2 mg weekly for glucose control. Wegovy injection maintenance is indication-specific: for adult weight reduction, 1.7 mg or 2.4 mg weekly, with 2.4 mg recommended. The current label permits 7.2 mg weekly for adults who tolerate 2.4 mg for at least four weeks when additional weight reduction is clinically indicated.

Daily tablet strengths use a different scale. Ozempic tablets start at 1.5 mg daily and progress to 4 mg, with 9 mg an option for additional glucose control. Wegovy tablets progress through 1.5, 4 and 9 mg to 25 mg daily maintenance. A larger number on a tablet is not a measure of superiority over an injection. Ozempic injection, Ozempic tablets, Wegovy

Your prescriber must manage any switch. See the semaglutide dosing guide and missed-dose guide; even catch-up instructions differ between formulations.

Is semaglutide a GLP-1?

Yes. Semaglutide activates the GLP-1 receptor. GLP-1 is a hormone involved in glucose regulation and appetite; the medication class includes other ingredients such as liraglutide and dulaglutide. Tirzepatide activates both GIP and GLP-1 receptors. The class name does not identify the right medicine for a person. Read how tirzepatide works.

Where compounded semaglutide fits

Compounded semaglutide is not Ozempic, Wegovy or a generic equivalent. FDA does not review compounded preparations for safety, effectiveness and quality before marketing. Approved-product studies cannot establish equivalent outcomes for a compounded finished product. FDA says compounding should address medical needs that an available approved drug cannot meet; price alone does not establish that need. FDA: compounded semaglutide and dosing risks

Ask the prescriber why a specific preparation is appropriate and ask the pharmacy to explain its concentration, measurement and storage. Do not transfer branded dosing or tablet instructions to it. Our compounded semaglutide explainer covers the distinction.

What to ask before choosing a treatment

• What condition are we treating, and is this exact product approved for it?
• What medical history, medicines or pregnancy plans affect the choice?
• What dose, formulation and device will I receive?
• What does insurance actually cover, and what is the cost for the full supply and later refills?

Insurance coverage is plan-specific; the ingredient name does not guarantee payment. Use the no-insurance cost guide and current REMEVi pricing for the financial questions. For oral options, see Foundayo versus Wegovy pills.

REMEVi offers care in English and Spanish in 49 states and Washington, DC, excluding Louisiana. Clinician-required GLP-1 labs are included. A licensed clinician reviews eligibility before prescribing. See if you qualify.

This article is educational. Product approval does not establish that a medicine is appropriate for you, and individual results vary.